Spero Therapeutics (NASDAQ:SPRO) issued its quarterly earnings results on Thursday. The company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.10), Bloomberg Earnings reports. Spero Therapeutics had a negative return on equity of 34.34% and a negative net margin of 342.70%. The business had revenue of $2.16 million during the quarter, compared to analyst estimates of $6.95 million.
SPRO stock traded down $0.18 during midday trading on Friday, reaching $9.23. The stock had a trading volume of 21,610 shares, compared to its average volume of 43,311. The firm has a fifty day moving average price of $10.88. The company has a current ratio of 17.48, a quick ratio of 17.48 and a debt-to-equity ratio of 0.04. The stock has a market cap of $165.77 million, a P/E ratio of -3.55 and a beta of 2.08. Spero Therapeutics has a 52-week low of $5.52 and a 52-week high of $14.48.
Several equities analysts recently weighed in on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 price target on shares of Spero Therapeutics in a report on Thursday, May 9th. ValuEngine upgraded Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 17th. Finally, TheStreet lowered Spero Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, July 29th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $19.50.
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Further Reading: What is a conference call?
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.